Business Wire

DE-CSC

17.11.2020 13:02:04 CET | Business Wire | Press release

Share
Holiday Shopping Warning: Simple Typos Can Lead Consumers and Brands to Online Fraud, Counterfeit Goods, and Cyber Crime

CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division warning consumers that simple URL typos could lead to significant online fraud, counterfeit goods, and cyber crime during the holiday shopping season. The company identified and analyzed registered domain typos (misspellings) associated with the 10 largest online shopping brands in the world and found that over 70% of the 1,553 registered domain typos appear to be owned by third parties.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005233/en/

According to CSC’s new research , these third-party owned domains receive over five million visitors annually. In addition, 40% of these domains are using domain privacy services to mask or hide their ownership and identity, and close to 48% are configured with MX (mail) records that can be used for phishing and to intercept email. In its blog, CSC offers tips to both brand owners and consumers to protect themselves against fraudulent web properties and content.

A deep dive of the top 100 most visited typo domains shows they are being used in this manner:

  • 38% are pointing to advertising-related and pay-per-click web content, which can be used to spread malware via domain parking services
  • 27% had no live web content, yet 37% were configured to send and receive email with MX records
  • 15% were engaged in affiliate referrals, which means the brand owner could be targeted for unauthorized affiliate activity resulting in loss of revenue
  • 12% were pointing at shopping-related web content, which indicates that consumers could engage with nefarious retailers selling counterfeit goods while brand owners lose revenue
  • 8% were pointing toward malicious web content e.g., malware

During the holiday shopping season, just one hour of downtime can cost a business over $500,000 in lost revenue*. Despite this, many global eCommerce and shopping companies are still lacking basic domain security measures that could prevent this from happening. For instance, only 16% of the top 500 global eCommerce and shopping domains leverage domain name system (DNS) hosting redundancy, which could secure their online presence from a distributed denial of service (DDoS) attacks. In addition, only 18% use registry locks that prevent DNS hijacking attacks that could redirect consumers to alternate websites. Lastly, 40% of retailers do not use enterprise-class domain registrars. This is partially explained by the fact that 40% of the observed domains still rely on retail registrars that typically don’t provide advanced domain security features.

In light of the global pandemic, both consumers and leading brands have embraced online shopping as we head into the 2020 holiday season. As such, we wanted to call attention to how brands and consumers are at increased risk for a multitude of threat vectors associated with online fraud, counterfeits, revenue leakage and many other cyber criminal activities this year,” says Ihab Shraim, chief technology officer for CSC. “As evidenced by the sheer number of mail-in votes in the U.S. election, consumers are looking for safe alternatives to in-person interactions, and it’s important for brands to not only provide those digital channels, but also ensure they are secure from online threat vectors.”

“We’re delighted that companies like CSC are advocating for companies and online brands to put the necessary security protocols in place to protect not only their brand reputation, but their consumers, from online fraud and cyber crime,” says Daniel Eliot, director of Education and Strategic Initiatives at the National Cyber Security Alliance (NCSA). “The NCSA's mission is to educate consumers and businesses about these credible risks, and the importance of using recommended cyber security best practices. CSC’s research is also an important part of advocating for consumers, and showing the pervasive risk of these cyber attacks and fraudulent domains.”

Additional resources:

*gremlin.com/ecommerce-cost-of-downtime/

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system, digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/CSCSince1899/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye